General Information:

Id: 2,038 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Rattus norvegicus
BTO:0002809 L-6 myoblast cell
article
Reference: Wei Y et al.(2008) Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am. J. Physiol. Endocrinol. Metab. 294: E345-E351 [PMID: 18073321]

Interaction Information:

Comment ANG II treatment of L6 myotubes induced NF-kappaB activation and TNF-alpha production and decreased insulin-stimulated Akt activation and GLUT-4 glucose transporter translocation to plasma membranes. These effects were markedly diminished by treatment of myotubes with valsartan, the antioxidant N-acetylcysteine, NADPH oxidase-inhibiting peptide (gp91 ds-tat), or NF-kappaB inhibitor (MG-132).
Formal Description
Interaction-ID: 16228

drug/chemical compound

Acetylcysteine

increases_transport of

gene/protein

SLC2A4

to the plasma membrane, in skeletal muscle; after Ang II treatment, if stimulated by insulin
Drugbank entries Show/Hide entries for Acetylcysteine